IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 <i>In Vitro</i>-Reference-Cited by-同舟云学术

IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro

Published:2022-12-21 Issue:6 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Xu Siyi¹²,Huang Jinlan¹²,Xun Zhen¹²,Li Shiqi¹²,Fu Ya¹²,Lin Ni¹²³,Wu Wennan¹²,Chen Tianbin¹²,Liu Can¹²,Ou Qishui¹²^ORCID

Affiliation:

1. Department of Laboratory Medicine, Gene Diagnosis Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

2. Fujian Key Laboratory of Laboratory Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

3. First Clinical College, Fujian Medical University, Fuzhou, China

Abstract

Our study contributes new insights into the understanding of the functions and roles of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), which is one of the interferon-stimulated genes induced by hepatitis B virus infection in human hepatocytes and hepatocarcinoma cells, and may help to identify targeted genes promoting the efficacy of interferon alpha.

Funder

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Fujian Medical University

福建省卫生健康委员会 | Fujian Provincial Health Technology Project

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01557-22

Reference51 articles.

1. WHO. 2017. Global hepatitis report 2017. WHO, Geneva, Switzerland.